Curis (NASDAQ:CRIS) Announces Earnings Results

Curis (NASDAQ:CRISGet Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($2.03) EPS for the quarter, missing the consensus estimate of ($1.91) by ($0.12), RTT News reports. Curis had a negative return on equity of 153.93% and a negative net margin of 473.04%. The company had revenue of $2.70 million during the quarter, compared to the consensus estimate of $2.95 million. During the same quarter last year, the company posted ($2.40) earnings per share.

Curis Trading Down 2.3 %

Shares of Curis stock opened at $10.41 on Friday. The company has a 50-day moving average of $11.77 and a 200 day moving average of $10.86. Curis has a 1 year low of $3.80 and a 1 year high of $20.00.

Analyst Ratings Changes

Several brokerages have commented on CRIS. Truist Financial began coverage on shares of Curis in a report on Friday, November 17th. They issued a “buy” rating and a $26.00 price objective for the company. HC Wainwright decreased their price target on shares of Curis from $51.00 to $26.00 and set a “buy” rating for the company in a research note on Friday.

Get Our Latest Stock Report on CRIS

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CRIS. Swiss National Bank increased its stake in shares of Curis by 7.9% in the 1st quarter. Swiss National Bank now owns 162,500 shares of the biotechnology company’s stock worth $387,000 after acquiring an additional 11,900 shares in the last quarter. JPMorgan Chase & Co. grew its position in Curis by 656.2% during the 1st quarter. JPMorgan Chase & Co. now owns 317,379 shares of the biotechnology company’s stock valued at $756,000 after purchasing an additional 275,407 shares during the last quarter. PNC Financial Services Group Inc. purchased a new stake in Curis during the 1st quarter valued at about $143,000. BlackRock Inc. grew its position in Curis by 4.9% during the 1st quarter. BlackRock Inc. now owns 6,587,381 shares of the biotechnology company’s stock valued at $15,677,000 after purchasing an additional 306,340 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Curis by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 4,241,608 shares of the biotechnology company’s stock valued at $10,095,000 after purchasing an additional 38,980 shares during the last quarter. 25.41% of the stock is currently owned by institutional investors.

Curis Company Profile

(Get Free Report)

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.

Recommended Stories

Earnings History for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.